搜索
Silence Therapeutics PLC
SLN添加自选
10.390USD
-0.110-1.05%
收盘 07/02, 13:00（美东）报价延迟15分钟
490.76M总市值
亏损市盈率 TTM
关于 Silence Therapeutics PLC 公司
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Silence Therapeutics PLC简介
公司代码SLN
公司名称Silence Therapeutics PLC
上市日期Jan 05, 2010
CEOTooman (Craig A)
员工数量116
证券类型Depository Receipt
年结日Jan 05
公司地址72 Hammersmith Road
城市LONDON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United Kingdom
邮编W14 8TH
电话442034576900
网址https://www.silence-therapeutics.com/
公司代码SLN
上市日期Jan 05, 2010
CEOTooman (Craig A)
Silence Therapeutics PLC公司高管
名称
名称/职务
职务
持股
持股变动
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
常见问题
Silence Therapeutics PLC的前五大股东是谁？
Silence Therapeutics PLC 的前五大股东如下：Mr. David Jakob (Dave) Lemus, CPA
有多少机构持有Silence Therapeutics PLC(SLN)的股份？
截至2026Q1，共有147家机构持有Silence Therapeutics PLC的股份，合计持有的股份价值约为19.17M，占公司总股份的40.59%。与2025Q4相比，机构持股有所增加，增幅为-12508865.00。